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Clinical significance of tacrolimus 
intra‑patient variability on kidney 
transplant outcomes according 
to pre‑transplant immunological 
risk
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High intra‑patient variability (IPV) of tacrolimus trough concentrations is increasingly recognized as 
a predictor of poor long‑term outcomes in kidney transplant. However, there is a lack of information 
regarding the association between tacrolimus IPV and graft outcomes according to immunological 
risk. We analyzed tacrolimus IPV using the coefficient of variability from months 6–12 after 
transplantation in 1080 kidney transplant recipients. Patients were divided into two immunological 
risk groups based on pre‑transplant panel reactive antibodies and donor‑specific antibodies. High 
immunological risk was defined as panel reactive antibodies ≥ 20% or the presence of donor‑specific 
antibodies. The effects of tacrolimus IPV on graft outcomes were significantly different between 
low and high immunological risk patients. A multivariable Cox regression model confirmed that high 
tacrolimus IPV was an independent risk factor for graft failure in the high risk group (HR, 2.90; 95% CI, 
1.42–5.95, P = 0.004). In the high risk group, high tacrolimus IPV was also significantly associated with 
increased risk of antibody‑mediated rejection (P = 0.006). In contrast, death‑censored graft survival 
and antibody‑mediated rejection in the low immunological risk group was not significantly different 
by tacrolimus IPV. High tacrolimus IPV significantly increases the risk of graft failure and antibody‑
mediated rejection in patients with high immunological risk.
Despite significant advances in short-term outcomes, long-term kidney transplantation (KT) outcomes remain 
 suboptimal1,2. Beyond the first year post transplantation, approximately 3–5% of grafts are lost annually. Although 
the causes of late graft loss are multifactorial, alloimmune-mediated injury and adverse effects of immunosup-
pressive medications are major  contributors3–5. As human leukocyte antigens (HLA) are the most important 
alloantigens in transplantation, transplant recipients have varying immunological risks according to donor-
recipient HLA matching and previous sensitization. Therefore, tailored immunosuppressive treatment for a 
given patient with varying immunological risks remains a critical unmet  need6–8. Unfortunately, current immu-
nosuppressive treatment is based on center-specific protocols rather than the immunological risk profile of a 
given  patient9.
The immunosuppressant tacrolimus is the cornerstone of the immunosuppression regimen in solid organ 
transplantation to prevent graft rejection and graft  loss10. However, tacrolimus has a narrow therapeutic window 
with high inter- and intra-patient variability (IPV), requiring close monitoring of blood trough  concentrations11. 
Patients with high tacrolimus IPV may be at risk of underexposure and alloimmune-mediated injury or overex-
posure and toxicity. A growing body of evidence suggests that high tacrolimus IPV is associated with poor graft 
 outcomes12,13. Therefore, tacrolimus IPV is not only a useful tool to identify patients with a greater risk but also 
one of the most important modifiable risk factor for long-term graft  outcomes14.
Tailored immunosuppressive strategy involves finding the lowest effective dose of immunosuppressive medi-
cation to control the alloimmune response while minimizing drug  toxicity15. Immunological risk of individual 
patients is a key determinant for tailored immunosuppressive  treatment16. In this context, the clinical significance 
OPEN
1Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea. 2Department of Internal 
Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. 3These authors contributed equally: Eun 
Jin Kim and Soo Jin Kim. *email: laplaine@yuhs.ac
2
Vol:.(1234567890)
Scientific Reports |        (2021) 11:12114  | https://doi.org/10.1038/s41598-021-91630-4
www.nature.com/scientificreports/
of tacrolimus IPV should be assessed according to immunological risk. However, there is a lack of information 
regarding the clinical significance of tacrolimus IPV on graft outcomes according to immunological risk. In the 
present study, we evaluate the association between tacrolimus IPV and graft outcomes and rejection in low- and 
high immunological risk patients.
Results
Baseline characteristics. After implementing the inclusion/exclusion criteria, 1080 patients who under-
went KT with tacrolimus-based immunosuppressive therapy were included in this study. Patients were divided 
into low- and high immunological risk groups according to peak panel reactive antibodies (PRA) and pres-
ence of donor-specific anti-HLA antibodies (DSA; high immunological risk was defined as PRA ≥ 20% or the 
presence of DSA). The baseline characteristics of patients are presented in Table 1. Compared to the low-risk 
group, immunologically high-risk patients were more likely to be older, female, and have longer dialysis vintage. 
The proportion of re-transplant cases and deceased donor KTs were significantly higher in the immunologi-
cally high-risk group than in the low-risk group. The median peak PRA of the high-risk group was 54% (IQR, 
30.0–84.0). Of the high-risk group patients, 70 had pre-transplant DSA (22.4%). No significant differences in 
HLA mismatch, donor age, and tacrolimus formulation were observed between the two groups. The use of anti-
thymocyte globulin for induction was significantly more common for patients in the high-risk group than for 
those in the low-risk group. The median follow-up duration was 82 months (IQR, 48.0–122.8).
Tacrolimus trough level and IPV. A total of 9059 tacrolimus trough concentrations were analyzed. The 
overall median number of trough concentration measurements per patient between 6 and 12 months after KT 
was 8.0 (IQR, 7.0–9.0). The mean tacrolimus trough level was 6.2 ± 2.0 ng/mL for the entire cohort, 6.2 ± 2.0 ng/
mL for low immunological risk patients, and 6.3 ± 1.9 ng/mL for high immunological risk patients (P = 0.464). 
The median tacrolimus IPV was 21.0% (IQR, 15.9–27.6) for the entire cohort, 21.0% (IQR, 16.0–27.7) for the 
Table 1.  Baseline characteristics of patients. Values are expressed as n (%), mean ± SD or median (IQR) 
depending on the data type. HLA Human leukocyte antigen, PRA Panel reactive antibodies, TAC Tacrolimus, 
IPV Intrapatient variability, CV Coefficient of variability.
Variables Low immunological risk (N = 763) High immunological risk (N = 317) P
Female, n (%) 242 (31.7) 188 (59.3)  < 0.001
Age, years 45.1 ± 12.1 47.9 ± 11.6  < 0.001
Body mass index, kg/m2 22.9 ± 3.4 22.0 ± 3.2  < 0.001
Mismatch HLA-A, B, DR 0.661
 1–2 170 (22.3) 78 (24.6)
 3–4 454 (59.5) 180 (56.8)
 5–6 139 (18.2) 59 (18.6)
Peak %PRA, median (IQR) 0 (0–2.0) 54 (30.0–84.0)  < 0.001
Re-transplant, n (%) 43 (5.6) 58 (18.3)  < 0.001
Dialysis vintage, months 38.0 ± 52.3 63.0 ± 62.4  < 0.001
Deceased donor, n (%) 184 (24.1) 149 (47.0)  < 0.001
Female donor, n (%) 401 (52.6) 136 (42.9) 0.004
Donor age, years 43.2 ± 12.0 44.6 ± 13.3 0.120
Induction agent, n  (%)
 No 41 (5.4) 1 (0.3)  < 0.001
 Basiliximab 660 (86.5) 240 (75.7)
 Anti-thymocyte globulin 62 (8.1) 76 (24.0)
Mean TAC IPV, CV% 23.0 ± 10.4 22.5 ± 9.8 0.503
 High TAC IPV, n (%) 146 (19.1) 62 (19.6) 0.872
Mean TAC concentration, ng/mL 6.2 ± 2.0 6.3 ± 1.9 0.464
Dose of TAC, mg/day 4.1 ± 2.2 4.0 ± 2.0 0.493
TAC concentration to dose ratio 2.1 ± 1.9 2.1 ± 1.4 0.865
TAC formulation 0.100
 Twice daily TAC 644 (85.4%) 273 (89.2%)
 Once daily TAC 110 (14.6%) 33 (10.8%)
Co-medication
 HMG CoA reductase inhibitor 386 (50.6%) 171 (53.9%) 0.315
 Proton pump inhibitor 46 (6.0%) 30 (9.5%) 0.044
 Diuretics 72 (9.4%) 53 (16.7%) 0.001
 Anticoagulants or antiplatelet drugs 90 (11.8%) 54 (17.0%) 0.021
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low-risk cohort, and 21.0% (IQR, 15.6–27.5) for the high-risk group. The proportion of patients with high tac-
rolimus IPV [coefficient of variation (CV) > 30%] was not significantly different between the two groups (19.1% 
vs. 19.6%). There was no significant difference in tacrolimus concentration to dose ratio between the two groups.
To investigate potential risk factors associated with high tacrolimus IPV, we performed multivariable logistic 
regression analysis (Table 2). Recipient age, sex, BMI, tacrolimus trough level, serum albumin, and renal func-
tion were not associated with high tacrolimus IPV. Low hematocrit levels at 12 months post-transplantation, 
proton pump inhibitor, and high tacrolimus concentration to dose ratio were significantly associated with high 
tacrolimus IPV.
Tacrolimus IPV and graft outcomes. Throughout the follow-up period, 130 graft losses occurred (93 
graft failures and 37 patient deaths). The association between tacrolimus IPV and death-censored graft survival 
was evident in the high immunological risk group (Fig. 1). Death-censored graft survival in the high immuno-
logical risk group was significantly impaired with high tacrolimus IPV (P < 0.001). A multivariable Cox regres-
sion analysis confirmed that high tacrolimus IPV was independently associated with graft failure in the high 
risk group [hazard ratio (HR), 2.90; 95% confidence interval (CI), 1.42–5.95; P = 0.004; Table 3]. Tacrolimus IPV 
was also associated with an increased risk of graft failure when assessed as continuous variables. In contrast, 
death-censored graft survival of the low immunological risk group was not significantly different according to 
tacrolimus IPV (P = 0.066). In the low-risk group, elderly recipient, estimated glomerular filtration rate (eGFR) 
at 1-year post-KT, deceased donor, and late-onset graft rejection were significant risk factors for graft failure, 
whereas high tacrolimus IPV was not associated with graft failure (Table 4).
Tacrolimus IPV and graft rejection. During the follow-up period, 294 graft rejection episodes [171 
antibody-mediated rejection (AMR) and 123 T-cell mediated rejection (TCMR)] occurred in 200 recipients. 
A total of 163 late-onset rejection (> 12  months after transplant, 51 active AMR, 58 chronic active AMR, 4 
chronic inactive AMR, and 50 TCMR) episodes occurred in 115 patients. Overall cumulative probabilities for 
late-onset AMR in high immunological risk group were significantly higher than in low immunological risk 
group (P = 0.035), whereas cumulative probabilities for late-onset TCMR between two groups were not signifi-
cantly different (P = 0.533). The association between tacrolimus IPV and late-onset AMR was significantly dif-
ferent between the two groups (Fig. 2). High tacrolimus IPV was significantly associated with increased risk of 
late-onset AMR in the high-risk group (P = 0.006). In the low-risk group, high tacrolimus IPV was not associated 
with late-onset AMR (P = 0.153). High tacrolimus IPV was not associated with late-onset TCMR in both groups.
Discussion
To date, there has been limited novel immunosuppressive drug development to improve long-term transplant 
 outcomes6. Until new therapeutic drugs are available, optimization of current immunosuppression based on 
immunological risk profile remains the only option to improve long-term graft outcomes after  KT17. In the 
present study, high tacrolimus IPV was significantly associated with an increased risk of graft failure in the high 
immunological risk group, whereas in the low immunological risk group it was not associated with graft failure. 
In addition, significant association between high tacrolimus IPV and late-onset AMR was observed only in the 
high-risk group.
Tacrolimus is the most commonly prescribed immunosuppressive drug for KT  patients1. It is known that 
tacrolimus is safe and effective only in a narrow therapeutic window. However, optimal tacrolimus trough levels 




OR (95% CI) P OR (95% CI) P
Elderly recipient (Age ≥ 60 years) 1.012 (0.645–1.588) 0.958
Female 0.956 (0.701–1.303) 0.775
Body weight, kg 0.992 (0.979–1.005) 0.208
Body mass index, kg/m2 0.981 (0.937–1.027) 0.407
High immunological risk group 1.044 (0.749–1.456) 0.799
TAC concentration to dose ratio 1.129 (1.043–1.222) 0.003 1.143 (1.049–1.246) 0.002
Once daily tacrolimus formulation 0.855 (0.535, 1.366) 0.513
Laboratory findings at 12 months
 Hematocrit, % 0.934 (0.908–0.960)  < 0.001 0.942 (0.914–0.971)  < 0.001
 Albumin, mg/dL 1.036 (0.993–1.080) 0.105 1.034 (0.990–1.080) 0.133
 eGFR < 60 mL/min/1.73m2 1.294 (0.951–1.759) 0.101 1.111 (0.790–1.562) 0.545
Proton pump inhibitor 2.349 (1.424, 3.874) 0.001 1.936 (1.114, 3.364) 0.019
Diuretics 1.378 (0.886, 2.144) 0.154 0.966 (0.585, 1.595) 0.892
Antiplatelet or anti-coagulant 0.963 (0.615, 1.508) 0.868
HMG CoA reductase inhibitor 0.821 (0.606, 1.111) 0.202
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Figure 1.  Overall graft survival according to tacrolimus IPV (A) high immunological risk group, (B) low 
immunological risk group.
Table 3.  Risk factors for graft loss in the high immunological risk group. eGFR Estimated glomerular filtration 
rate, TAC Tacrolimus, IPV Intrapatient variability, CV Coefficient of variation.
Variables
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Elderly recipient (Age ≥ 60 years) 3.631 (1.699–7.761) 0.001 3.095 (1.267–7.558) 0.013
eGFR at 1 year, mL/min/1.73m2 0.964 (0.946–0.982)  < 0.001 0.966 (0.947–0.986) 0.001
Re-transplant 1.257 (0.588–2.685) 0.556
Donor age, years 1.043 (1.011–1.076) 0.007 0.990 (0.957–1.025) 0.581
Deceased donor 2.399 (1.153–4.993) 0.019 1.892 (0.849–4.213) 0.119
Mean TAC trough concentration 1.033 (0.867–1.231) 0.712
High TAC IPV (CV > 30%) 3.172 (1.578–6.382) 0.001 2.904 (1.417–5.950) 0.004
Late-onset graft rejection 3.827 (1.843–7.947)  < 0.001 3.237 (1.511–6.932) 0.003
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Table 4.  Risk factors for graft loss in the low immunological risk group. eGFR Estimated glomerular filtration 
rate, TAC Tacrolimus, IPV Intrapatient variability, CV Coefficient of variation.
Variables
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Elderly recipient (Age ≥ 60 years) 2.033 (1.120–3.690) 0.020 2.259 (1.210–4.219) 0.011
eGFR at 1 year, mL/min/1.73m2 0.956 (0.943–0.969)  < 0.001 0.970 (0.956–0.984)  < 0.001
Re-transplant 0.668 (0.244–1.830) 0.433
Donor age, years 1.032 (1.012–1.053) 0.002 1.010 (0.987–1.034) 0.397
Deceased donor 1.741 (1.083–2.799) 0.022 1.717 (1.024–2.882) 0.041
Mean TAC trough concentration 1.019 (0.918–1.132) 0.721
High TAC IPV (CV > 30%) 1.565 (0.967–2.535) 0.068 1.040 (0.629–1.720) 0.879
Late-onset graft rejection 7.219 (4.653–11.201)  < 0.001 6.960 (4.356–11.120)  < 0.001
Figure 2.  Cumulative probability of late-onset antibody-mediated rejection according to tacrolimus IPV (A) 
high immunological risk group, (B) low immunological risk group.
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have not been clearly defined. In addition to a narrow and poorly defined therapeutic window, clinical use of 
tacrolimus is complicated by significant  IPV11. Since Borra et al. first described the negative effect of high tac-
rolimus IPV on graft outcomes, there is a growing body of literature to support the association between high 
tacrolimus IPV and deleterious graft  outcomes13,14,18. Previous studied have suggested that high tacrolimus IPV 
leads to inferior graft outcomes due to alloimmune-mediated  injury12,19. Therefore, the effects of tacrolimus IPV 
on graft outcome might be more pronounced in patients with high immunological risk than in those with low 
immunological risk. To utilize tacrolimus IPV measurements for tailored immunosuppression treatment, the 
patient’s immunological risk should be taken into account.
Several studies suggested that tacrolimus underexposure significantly increased the risk of alloimmune-
mediated injury according to immunological  risk20. Wiebe et al. reported a significant impact of tacrolimus 
trough concentrations on the development of de novo DSA based on immunological risk as determined by 
HLA-DR/DQ epitope  mismatch15. However, none of these studies analyzed tacrolimus IPV, which is associated 
with inferior graft outcomes. Our findings focused on the tacrolimus IPV extend previous findings of the impor-
tance of immunological risks in tailored immunosuppressive strategies. In the present study, clinical association 
between tacrolimus IPV and graft outcomes was more evident in patients with high immunological risk than in 
those with low immunological risk. Multivariable analysis revealed that high tacrolimus IPV was significantly 
associated with graft loss in the high immunological risk group. In the high-risk group, patients with high tac-
rolimus IPV were also at greater risk of AMR. Patients with low immunological risk were more likely to tolerate 
high tacrolimus IPV without developing AMR. This study highlights the importance of assessing immunological 
risk when creating tailored immunosuppressive strategies. To the best of our knowledge, this is the first study to 
assess the effect of tacrolimus IPV across a range of immunological risk groups.
In the present study, immunological risk was stratified by pre-transplant PRA and DSA, which are the most 
commonly used tests for determining immunological risk in clinical practice. We acknowledge that these tests for 
identifying patient risk for memory or alloimmune response is limited and the cut-off is  arbitrary21. We attempted 
to minimize misclassification by excluding immunologically incompatible KTs and zero-HLA mismatch KTs. 
Although significant advances in immunological tests, including complement fixation assays, non-HLA antibod-
ies, and HLA molecular mismatch have permitted more comprehensive immunological risk assessment, none 
of the tests are widely used in current clinical  practice15,22–24. Evidence supporting the added clinical benefit of 
these tests over traditional immunological tests remains controversial. Further studies are needed to evaluate 
the effects of tacrolimus IPV based on more accurate immunological assessment.
Several possible mechanisms for high tacrolimus IPV include medication non-adherence, drug-drug interac-
tion, food intake, gastrointestinal disorders, and changing  hematocrit18,25. Although medication non-adherence 
is a major determinant of high IPV, some degree of IPV has been identified, even in highly adherent  patients26. 
In the present study, low hematocrit level at the first post-transplant year and high tacrolimus concentration to 
dose ratio were significantly associated with high tacrolimus IPV. This finding is consistent with the fact that 
tacrolimus mainly distributes into and binds to erythrocytes. High tacrolimus IPV, irrespective of its cause, is an 
important risk factor for poor graft outcomes. Previous studies have shown that adherence-enhancing interven-
tions can improve tacrolimus  IPV18,27. Taken together, this suggests that patients classified as high immunological 
risk need tight monitoring and interventions such as educational support and simplified drug regimens.
The present study has some limitations that warrant consideration. First, retrospective single-center inves-
tigation limits the generalizability of this study. However, this made it possible to maintain homogeneity in 
immunosuppressive regimen, patient education, and follow-up protocol. Second, information about adherence 
is lacking. Although medication non-adherence is a major determinant of high IPV, it is not the sole cause of 
high  IPV26. In addition, objective adherence is difficult to measure in routine clinical practice. We attempted to 
evaluate other potential risk factors for high tacrolimus IPV. Third, de novo DSA were not systematically deter-
mined. We adopted de novo DSA monitoring in 2011, but prior to this time such measurements were limited 
due to national health insurance coverage and reimbursement. Despite the clinical significance of de novo DSA, 
there remains no consensus on how best to monitor de novo DSA after  transplantation21. Further prospective 
research is needed to identify the clinical significance of tacrolimus IPV on developing de novo DSA according 
to immunological risk.
In conclusion, high tacrolimus IPV significantly increases the risk of graft loss and late-onset AMR after KT, 
especially in high immunological risk patients. Our results support evaluation of tacrolimus IPV in the con-
text of each patient’s immunological risk. Using tacrolimus IPV to individualize immunosuppressive treatment 
and monitoring may improve long-term graft outcomes. Future clinical trials are warranted to fully assess this 
approach.
Methods
Study population. A total of 1578 patients (aged ≥ 18 years) who underwent KT under tacrolimus-based 
immunosuppression between January 2006 and December 2018 at the Severance Hospital, Seoul, Republic 
of Korea, were initially screened. Patients who underwent multi-organ transplantation, patients with positive 
crossmatch and/or ABO-incompatible KT, and zero-HLA mismatch KT patients were excluded. Patients who 
experienced graft loss within 6 months or who lacked sufficient data were also excluded. After applying these 
restrictions, 1080 patients were ultimately included in the study. These patients were grouped into low- and high 
immunological risk groups based on pre-transplant peak PRA and presence of DSA. High immunological risk 
was defined as PRA ≥ 20% or the presence of DSA (Fig. 3).
Immunosuppression. Immunosuppression was performed according to center  protocol28. Most patients 
received induction immunosuppression with basiliximab (20 mg on days 0 and 4 post-transplant) or anti-thy-
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mocyte globulin (1.5 mg/kg per day for 4 days). Maintenance immunosuppression for all patients consisted 
of tacrolimus, prednisolone, and mycophenolate mofetil (MMF). The initial tacrolimus dosage (0.1  mg/kg) 
was administered orally twice daily. Subsequent doses were adjusted to maintain a target trough concentra-
tion between 5 and 8 ng/ml. The initial dose of methylprednisolone (500–1000 mg) was gradually reduced and 
replaced with oral prednisolone (5–10 mg/day) during the first 3 weeks after transplantation. MMF was started 
at 1.0–1.5 g/day and subsequently adjusted to minimize adverse events such as neutropenia or gastrointestinal 
side effects.
Clinical and laboratory measurements. Pre-transplant PRA and DSA were measured as described 
 previously24. Briefly, PRA testing was performed using Luminex PRA assay kits (LIFECODES LifeScreen Deluxe 
and Class I and Class II ID, Immucor Transplant Diagnostics, Stamford, CT, USA) and was presented as percent 
PRA. DSA were detected using Lifecodes LSA Class I and Class II kits (Immucor Transplant Diagnostic) or 
LabScreen Single Antigen (One Lambda, Canoga Park, CA, USA) according to the manufacturers’ protocols. 
The strength of each DSA was determined at the maximum mean fluorescence intensity (MFI) value and a MFI 
of > 1000 was considered positive.
Routine biochemical tests, including the assessment of tacrolimus trough concentrations, were performed 
every month during the first year post transplantation and every 3 months thereafter. Tacrolimus trough concen-
trations were determined using a microparticle enzyme immunoassay [Tacrolimus II MEIA/IMx analyzer (Abbott 
Laboratories, Chicago, IL, USA) until May 8, 2008; Dimension RxL (Siemens, Munich, Germany) between May 
9, 2008 and February 25, 2013; Architect i2000 (Abbott Laboratories) from February 26, 2013 onward]. Errone-
ously high tacrolimus concentrations (> 20 ng/mL) resulting from taking morning doses before blood sampling 
were excluded. Tacrolimus IPV was estimated by calculating the CV according to the following equation: CV 
(%) = (standard deviation/mean tacrolimus trough concentration) × 100. Mean concentrations were calculated 
using outpatient tacrolimus concentrations between 6 and 12  months14. We used a CV cutoff value of 30% for 
high tacrolimus  IPV12,26.
eGFR was evaluated using the Chronic Kidney Disease Epidemiology Collaboration  equation29. Renal biopsies 
were performed in cases of acute allograft dysfunction (> 30% increase in serum creatinine levels compared with 
baseline or proteinuria > 500 mg/day). Allograft biopsy samples were processed using light, immunofluorescent, 
and electron microscopy at the time of biopsy. All allograft rejections were confirmed by biopsy and classified 
into AMR and TCMR according to the most recent Banff criteria at the time of  biopsy30.
Definition and study endpoints. The primary study endpoint was death-censored graft survival. The 
secondary endpoints included late-onset AMR and TCMR. Graft failure was defined as the return to long-term 
dialysis or re-transplantation. Graft survival was calculated from the date of transplantation to the date of graft 
failure, loss to follow-up, or December 31, 2020 (the end of the follow-up period). In cases of death with a func-
Figure 3.  Study diagram.
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tioning graft, graft survival was censored at the time of death. Late-onset rejection was defined as any biopsy-
confirmed rejection that occurred more than 12 months post-transplantation.
Statistical analysis. Data were expressed as frequency, mean, and standard deviation, or as the median 
and IQR, depending on the data type. Chi-square or Fisher’s exact tests were used as appropriate to compare cat-
egorical variables. Continuous variables were compared using Student’s t-test for parametric data or the Mann–
Whitney test for nonparametric data. Multivariable logistic regression was performed using the high tacrolimus 
IPV (CV > 30%) as an outcome variable. Covariates included baseline characteristics and laboratory findings at 
12 months post-transplantation. Death-censored graft survival and cumulative probability of AMR were ana-
lyzed using Kaplan–Meier curves and the log-rank test. Cox proportional hazard regression models were used 
to evaluate the associations between tacrolimus IPV and time to graft loss. Statistical analyses were performed 
using SPSS software (version 25.0; SPSS Inc., Chicago, IL, USA). P < 0.05 was considered significant.
Ethics statement. All study procedures were conducted in accordance with the Declaration of Helsinki 
and were approved by the Institutional Review Board of Severance Hospital (2020-2851-001). Informed consent 
was waived by the Institutional Review Board of Severance Hospital because of the study’s retrospective design.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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